Becton, ディキンソン&カンパニーはQ4収益の見積りを破り,強大な"Bay"株式評価を維持した. Becton, Dickinson and Company beat Q4 earnings estimates, maintaining a strong "Buy" stock rating.

Becton, Dickinson and Company (BDX) は,数人の施設投資家が保有権の調整を行い,一部は買物その他の株式を販売している. Becton, Dickinson and Company (BDX) saw several institutional investors adjust their holdings, with some buying and others selling shares. 同社は4四半期に株当たり3.43ドルの利益を報告し,アナリストの推定を0.43ドル上回った. The company reported fourth-quarter earnings of $3.43 per share, beating analyst estimates by $0.43. BDXは,医薬品や機器で知られるBDXは65.42億円の市場キャップを持ち,1株あたり440ドルの四分の一の配当を支払っている. BDX, known for medical supplies and devices, has a market cap of $65.42 billion and pays a quarterly dividend of $1.04 per share, with a yield of 1.83%. 株式は"Bay"の評価と平均価格目標278.29. The stock has a consensus "Buy" rating and an average price target of $278.29.